Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari fo... Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Show more
โ Dans l'ensemble de la population, rรฉduction de 28 % du composite primaire de la mortalitรฉ toutes causes confondues et des troubles cardiovasculaires rรฉcurrents, et rรฉduction de 31 % et 36 % de...
โ In der Gesamtpopulation wurde eine 28-prozentige Reduktion des primรคren Komposits aus Gesamtmortalitรคt und wiederkehrenden kardiovaskulรคren Ereignissen sowie eine 31-prozentige und...
โ In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells Fargo 2024...
โ Das Unternehmen richtet am 30. August 2024 um 13.00 Uhr (BST), 8.00 Uhr (ET), eine Konferenzschaltung zur Erรถrterung der Ergebnisse ein โ Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 12.88 | 4.93486590038 | 261 | 279.85 | 259.006 | 587825 | 272.51335741 | CS |
4 | -4.33 | -1.5563782754 | 278.21 | 287.5499 | 244.88 | 925784 | 265.6622892 | CS |
12 | 33.88 | 14.1166666667 | 240 | 287.5499 | 231.01 | 910742 | 259.47230608 | CS |
26 | 126.24 | 85.5052831211 | 147.64 | 287.5499 | 141.975 | 863586 | 217.48508684 | CS |
52 | 97.88 | 55.6136363636 | 176 | 287.5499 | 141.975 | 807368 | 194.05163685 | CS |
156 | 85.91 | 45.7041017184 | 187.97 | 287.5499 | 117.58 | 798221 | 188.38692587 | CS |
260 | 188.98 | 222.591283863 | 84.9 | 287.5499 | 73.32 | 736067 | 170.28782764 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.